Antisense Oligonucleotide Therapeutics Market A New Era of Precision Medicine

Antisense Oligonucleotide Therapeutics Market worth $ 64.64 Billion by 2030 - Exclusive Report by Insight Analytics

Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global Antisense Oligonucleotide Therapeutics Market- by Therapy (Monotherapy and Combination), Molecule Target Indication (DNA Molecule and RNA Molecule), Target Indication (Duchenne Muscular Atrophy, Spinal Muscular Atrophy, Familial Chylomicronemia Syndrome, Amyotrophic Lateral Sclerosis, Familial Partial Lipodystrophy, Hereditary Transthyretin-Mediated (hatter) Amyloidosis, Huntington's Disease and Others), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

Get a free sample copy of the report: https://www.insightaceanalytic.com/request-sample/1245

Antisense oligonucleotide (ASO) therapeutics are revolutionizing the field of medicine by offering a targeted approach to treating diseases. Insight Analytics estimates the global market for ASO therapeutics to reach a staggering US$64.64 billion by 2030, boasting a compound annual growth rate (CAGR) of 12.9% (2024-2031).

These innovative therapies utilize short, single-stranded DNA or RNA molecules to target messenger RNA (mRNA) within cells. By acting at this level, before protein formation, ASOs can inhibit the expression of disease-causing genes. This mechanism offers a highly specific approach to treatment, making ASOs a valuable tool for combating various conditions.

Several factors are propelling the growth of the ASO therapeutics market:

• Rising Prevalence of Neurological Disorders and Aging Populations: The increasing incidence of neurological disorders and the trend of aging populations create a growing demand for ASO therapies with the potential to address these challenges.

• Increased R&D Funding and Consumer Acceptance: Growing investments in research and development for ASOs, coupled with rising consumer acceptance of these novel therapies, are significantly impacting market growth.

• FDA Regulatory Approvals and Mergers & Acquisitions: The Food and Drug Administration's (FDA) issuance of multiple regulatory licenses for innovative ASO medications is a major boost to the industry. Additionally, mergers and acquisitions aimed at expanding product portfolios are expected to further propel the market forward.

However, the market also faces challenges:

• Accessibility of Synthetic Chemicals and High Treatment Costs: Ensuring accessibility of the synthetic chemicals required for ASO production and addressing the high cost of these therapies are crucial hurdles to overcome.

• Evolving Regulatory Landscape: Navigating the evolving regulatory landscape for ASO therapies presents another challenge for market growth.
Despite these obstacles, significant opportunities exist:

• Investment by Key Players: Investments by prominent players in the field are expected to create lucrative revenue growth opportunities for companies engaged in ASO therapeutics.

Geographically, the ASO therapeutics market is expected to see significant growth in both North America and Europe:

• Europe: The increasing acceptance of novel ASO medications and strategic acquisitions by European companies to strengthen their ASO product lines are driving market expansion in this region.

• North America: High levels of financial investment by biotechnology companies in developing RNAi treatments, coupled with partnerships and licensing agreements between large pharmaceutical companies and smaller players, position North America for substantial market growth.
This report delves into the ASO therapeutics market, exploring its key drivers, challenges, and future prospects. It sheds light on the transformative potential of ASO therapies and their role in shaping the future of targeted medicine.

Major market players operating in the Antisense Oligonucleotide Therapeutics market include Pharmaceuticals, Inc., Sarepta Therapeutics, Biogen, Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Sarna Therapeutics GmbH, Arrowhead Pharmaceuticals, Inc., Atlantic Pharmaceuticals, Inc., GlaxoSmithKline plc, Gerona Corporation, Gradualist, ICO Therapeutics, Aptos Biosciences, Enzo Pharmaceuticals, Inc., Bio-Path Holdings, Inc., Gene Signal International SA, Marina Biotech, mirage Therapeutics, Inc., Synodic, Inc., Oncogene Pharmaceuticals Inc., Pharm axis Ltd, Regulus Therapeutics Inc., Reran Pharmaceuticals, Inc., and RI Pharmaceuticals, among others.

Recent collaborations and agreements in the market:

• In January 2021, MilliporeSigma (US) acquired AmpTec, a well-known German business specializing in contract development and manufacturing mRNA (CDMO).

• In August 2019, Integrated DNA Technology released tools- oligo pools, a set of 350-nucleotide-long, high-quality DNA oligonucleotides (US).

Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1245
Market Segments

Global Antisense Oligonucleotide Therapeutics Market, by Therapy, 2022-2030 (Value US$ Mn)

• Monotherapy
• Combination

Global Antisense Oligonucleotide Therapeutics Market, by Molecule Target Indication, 2022-2030 (Value US$ Mn)

• DNA Molecule
• RNA Molecule

Global Antisense Oligonucleotide Therapeutics Market, by Target Indication, 2022-2030 (Value US$ Mn)

• Duchenne Muscular Atrophy
• Spinal Muscular Atrophy
• Familial Chylomicronemia Syndrome
• Amyotrophic Lateral Sclerosis
• Familial Partial Lipodystrophy
• Hereditary Transthyretin-Mediated (hatter) Amyloidosis
• Huntington's Disease
• Others

Global Antisense Oligonucleotide Therapeutics Market, by Region, 2022-2030 (Value US$ Mn)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Antisense Oligonucleotide Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• U.S.
• Canada

Europe Antisense Oligonucleotide Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Antisense Oligonucleotide Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Antisense Oligonucleotide Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa Antisense Oligonucleotide Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• GCC Countries
• South Africa
o Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global Antisense Oligonucleotide Therapeutics market
 To receive an industry overview and future trends in the Antisense Oligonucleotide Therapeutics market
 To analyze the Antisense Oligonucleotide Therapeutics market drivers and challenges
 To get information on the Antisense Oligonucleotide Therapeutics market value (US$Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the Antisense Oligonucleotide Therapeutics market industry

For More Information @ https://www.insightaceanalytic.com/customisation/1245

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.